Does surgery for breast cancer induce angiogenesis and thus promote metastasis?

Oncology

Volumn 81, Issue 3-4, 2011, Pages 199-205

  Park, Youngjin ^a   Kitahara, Tomoaki ^a   Takagi, Ryuichi ^a   Kato, Ryoji ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Breast cancer; Micrometastasis; Regulators of angiogenesis; Surgery induced angiogenesis; Tumor dormancy

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOSTATIN; BETA INTERFERON; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; NEU DIFFERENTIATION FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SCATTER FACTOR; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UFT; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CELL CYCLE G0 PHASE; CELL DIVISION; CELL PROLIFERATION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; MACROPHAGE; METASTASIS; MICROMETASTASIS; NONHUMAN; ONCOGENE; POINT MUTATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM MICROMETASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84255166990     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333455     Document Type: Review

References (28)

1. Frank M, Schabel FM Jr: Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 1967; 40: 558-568.
2. Baba H, Maehara Y, Takeuchi H, Inutsuka S, Okuyama T, Adachi Y, Akazawa K, Sugimachi K: Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery 1995; 117: 165-169.
3. Husemann Y, Geigl J.B, Schubert F, Musiani P, Meyer M, Burghart E, Fomi G, Eils R, Fehm T, Riethmuller G, Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
4. Retsky MW, Demicheli R, Swartzendruber DE, Bame PD, Wardwell RH, Bonadonna G, Speer JF, Valagussa P: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 1997; 45: 193-202.
5. Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V: Assessment of highly angiogenetic and disseminated cancer cells in the peripheral blood in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004; 108: 620-627.
6. Garvin S, Dabrosin C: Tamoxifen inhibits secretion of vascular endothelial growth factor in vivo. Cancer Res 2003; 63: 8742-8748.
7. Furman HE, Maretzek AF, Goldberg I, Horowitz A, Degani H: Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelial growth. Cancer Res 1994; 54: 5511-5514.
8. Schabel FM Jr: Concepts for treatment of micrometastasis developed in moraine systems. Am J Roentgenol 1976; 126: 500-511.
9. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
10. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA: Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
11. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
12. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
13. Abdollahi A, Folkman J: Evading tumor evasion: Current concepts and perspectives of anti-angiogenetic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
14. Demicheli R, Retsky MW, Hrushesky WJM, Baum M, Gukas ID: The effects of surgery on tumor growth: A century of investigations. Ann Oncol 2008; 19: 1821-1828.
15. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
16. Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E, Zamarchi R, Chieco-Bianchi L, Amadori A: Interruption of tumor dormancy by a transient angiogenetic burst within the tumor microenvironment. Proc Natl Acad Sci USA 2006; 103: 4216-4221.
17. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ: Wound-induced tumor progression: A probable role in recurrence after tumor resection. Arch Surg 1998; 133: 383-389.
18. Maniwa Y, Okada M, Ishii N, Kiyooka K: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998; 114: 1668-1675.
19. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T: Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer 2002; 5: 137-141.
20. Wu FPK, Hoeckman K, Meijer S, Cuesta MA: VEGF and endostatin levels in wound fluids and plasma after breast surgery. Angiogenesis 2003; 6: 255-257.
21. Kumar R, Yarmand-Bagheri R: The role of Her2 in angiogenesis. Semin Oncol 2001; 289: 27-32.
22. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ: COX-2 expression is associated with an aggressive phenotype of ductal carcinoma in situ. Br J Cancer 2004; 90: 423-429.
23. Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, Higaki K, Ogita M, Asaga T, Inaji H, Komichi H, Kohno N, Yamazaki K, Tanaka F, Ito T, Nishikawa H, Osaki A, Koyama H, Suzuki T: Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: A comparative study. Br J Cancer 2009; 101: 598-604.
24. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F: Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951-2958.
25. George F, Brouqui P, Boffa MC, Mutin M, Drancourt M, Brisson C, Raoult D, Sampol J: Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 1993; 82: 2109-2116.
26. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, Voest EE: Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15: 139-145.
27. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-4346.
28. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: 2185-2191.